Loading...

PE anti-mouse TNF-α Antibody PE anti-mouse TNF-α Antibody

Pricing & Availability
Clone
MP6-XT22 (See other available formats)
Regulatory Status
RUO
Other Names
Tumor necrosis factor-α, Cachectin, Necrosin, Macrophage cytotoxic factor (MCF), Differentiation inducing factor (DIF), TNFSF-2, TNF-a, TNF-alpha
Isotype
Rat IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
MP6-XT22_PE_TNF-a_Antibody_FC_1_100913
PMA + Ionomycin-stimulated C57BL/6 mouse splenocytes (in the presence of monensin) were stained with CD3 APC, fixed, permeabilized and then stained with TNF-α (clone MP6-XT22) PE (top) or rat IgG1, κ PE isotype control (bottom).
  • MP6-XT22_PE_TNF-a_Antibody_FC_1_100913
    PMA + Ionomycin-stimulated C57BL/6 mouse splenocytes (in the presence of monensin) were stained with CD3 APC, fixed, permeabilized and then stained with TNF-α (clone MP6-XT22) PE (top) or rat IgG1, κ PE isotype control (bottom).
  • MP6-XT22_PE_TNF-a_Antibody_FC_2_101413
Compare all formats See PE spectral data
Cat # Size Price Quantity Check Availability Save
506305 25 µg DKK404
Check Availability


Need larger quantities of this item?
Request Bulk Quote
506306 100 µg DKK1414
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

TNF-α is secreted by macrophages, monocytes, neutrophils, T-cells, and NK-cells. Many transformed cell lines also secrete TNF-α. Monomeric mouse TNF-α is a 156 amino acid protein (N-glycosylated) with a reported molecular weight of 17.5 kD. TNF-α forms multimeric complexes; stable trimers are most common in solution. A 26 kD membrane form of TNF-α has also been described. TNF-α binding to surface receptors elicits a wide array of biologic activities including: cytolysis and cytostasis of many tumor cell lines in vitro, hemorrhagic necrosis of tumors in vivo, increased fibroblast proliferation, and enhanced chemotaxis and phagocytosis in neutrophils.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
E. coli-expressed, recombinant mouse TNF-α
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

ICFC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

ELISA Capture: The purified MP6-XT22 antibody is useful as the capture antibody in a sandwich ELISA when used in conjunction with the biotinylated Poly5160 antibody (Cat. No. 516003) as the detection antibody and recombinant mouse TNF-α (Cat. No. 575209) as the standard.
Flow Cytometry6,11,12:The fluorochrome-labeled MP6-XT22 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify TNF-a-producing cells within mixed cell populations.
Neutralization1,5,10,16,17:The MP6-XT22 antibody can neutralize the bioactivity of natural or recombinant TNF-α. The LEAF™ purified antibody (Endotoxin < 0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse TNF-α bioactivity in vivo and in vitro(Cat. No. 506310). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 506332) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).
Additional reported applications (for the relevant formats) include: Western blotting, immunohistochemical staining of paraformaldehyde-fixed, saponin-treated frozen tissue sections7-9 in vivo detection5, immunofluorescence, and immunocytochemistry.
Note: For testing mouse TNF-α in serum, plasma or supernatant, BioLegend's ELISA Max™ Sets (Cat. No. 430901) are specially developed and recommended.

Application References
  1. Abrams J, et al. 1992. Immunol. Rev. 127:5. (Neut)
  2. Abrams J, et al. 1995. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.20
  3. Mo X, et al. 1995. J. Virol. 69:1288.
  4. Sarawar S, et al. 1994. J. Immunol. 153:1246.
  5. Via C, et al. 2001. J. Immunol. 167:6821. (Neut)
  6. Infante-Duarte C, et al. 2000 J. Immunol. 165:6107. (FC)
  7. Jacobs M, et al. 2000. Immunology 100:494. (IHC)
  8. Marinova-Mutachieva L, et al. 1997. Clin. Exp. Immunol. 107:507. (IHC)
  9. Williams RO, et al. 2000. J. Immunol. 165:7240. (IHC)
  10. Scanga CA, et al. 1999. Infect. Immun. 67:4531. (Neut)
  11. Akilov OE, et al. 2007. J. Leukoc. Biol. 2007;10.1189/jlb.0706439. (FC)
  12. Lawson BR, et al. 2007. J. Immunol. 178:5366. (FC)
  13. Patole PS, et al. 2005. J. Am. Soc. Nephrol. 16:3273. PubMed
  14. Wu S, et al. 2005. Neurosci Lett. 394:158. PubMed
  15. Carlson MJ, et al. 2009. Blood 113:1365. PubMed
  16. Shivakumar P, et al. 2017. JCI Insight. 2:e88747 1. PubMed
  17. Kearney CJ, et al. 2017. Cell Death Differ. 10.1038/cdd.2017.94. PubMed
Product Citations
  1. Mendonça-Vieira LR, et al. 2021. Viruses. 13:. PubMed
  2. Zhou R, et al. 2022. EBioMedicine. 75:103762. PubMed
  3. Logan K Smith et al. 2018. Immunity. 48(2):299-312 . PubMed
  4. Djokić V, et al. 2019. Front Immunol. 9:2891. PubMed
  5. Darzianiazizi M, et al. 2020. Int J Mol Sci. 21:00. PubMed
  6. Asrat S, et al. 2014. PLoS Pathog. 10:1004229. PubMed
  7. Li B, Schmidt N 2016. PLoS One. 11: 0162427. PubMed
  8. Schenkel JM, et al. 2021. Immunity. 54:2338. PubMed
  9. Stone ET, et al. 2022. Cell Rep. 38:110388. PubMed
  10. Iberg CA, et al. 2022. Cell Rep. 39:110657. PubMed
  11. Lu R, et al. 2022. Scand J Immunol. 96:e13177. PubMed
  12. West HC, et al. 2022. Cell Rep. 39:110819. PubMed
  13. Blanas A, et al. 2022. iScience. 25:104719. PubMed
  14. Kang IH, et al. 2022. iScience. 25:104818. PubMed
  15. Balood M, et al. 2022. Nature. 611:405. PubMed
  16. Wei M, et al. 2022. Front Immunol. 13:1017574. PubMed
  17. Liu L, et al. 2022. Cell Biosci. 12:193. PubMed
  18. Huseni MA, et al. 2023. Cell Rep Med. 4:100878. PubMed
  19. Caslin HL, et al. 2023. Front Immunol. 13:984859. PubMed
  20. Cheng H, et al. 2023. Nat Metab. 5:314. PubMed
  21. Zander R, et al. 2022. Immunity. 55:475. PubMed
  22. Wight AE, et al. 2022. Proc Natl Acad Sci U S A. 119:e2200757119. PubMed
  23. Belk JA, et al. 2022. Cancer Cell. 40:768. PubMed
  24. Akhtar MN, et al. 2022. MBio. 13:e0330921. PubMed
  25. Pan Y, et al. 2023. Adv Sci (Weinh). 10:e2206792. PubMed
  26. Yu L, et al. 2023. Front Oncol. 13:1174713. PubMed
  27. Bhaskar A, et al. 2023. iScience. 26:106644. PubMed
  28. Xie J, et al. 2023. Mol Ther Oncolytics. 29:61. PubMed
  29. Liu W, et al. 2020. Mol Ther Oncolytics. 17:350. PubMed
  30. Wang Y, et al. 2021. Andrologia. 53:e14239. PubMed
  31. Wilfahrt D, et al. 2021. Elife. 10:. PubMed
  32. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  33. Wu T, et al. 2021. Mol Ther Oncolytics. 23:420. PubMed
  34. Zhou J, et al. 2019. Immunity. 50:403. PubMed
  35. Duan Q, et al. 2021. Front Cell Dev Biol. 9:761193. PubMed
  36. Chen L, et al. 2022. Mol Ther Oncolytics. 24:522. PubMed
  37. Liang S, et al. 2022. Acta Pharm Sin B. 12:2494. PubMed
  38. Harel M, et al. 2020. Cell. 179(1):236-250.e18.. PubMed
  39. Yang X, et al. 2021. Front Pharmacol. 12:771046. PubMed
  40. Lu Y, et al. 2019. Int J Mol Med. 43:2398. PubMed
  41. Álvaro de Mingo Pulido et al. 2018. Cancer cell. 33(1):60-74 . PubMed
  42. Wabitsch S, et al. 2021. STAR Protoc. 2:100517. PubMed
  43. Liu Q, et al. 2021. Cell Death Dis. 12:240. PubMed
  44. Liu X, et al. 2020. Nature. . PubMed
  45. Haque M, et al. 2021. STAR Protoc. 2:100264. PubMed
  46. Wu J, et al. 2020. Sci Adv. 6:eaba3458. PubMed
  47. Suzuki M, et al. 2021. Sci Adv. 7:. PubMed
  48. Chen D, et al. 2018. Nat Commun. 9:873. PubMed
  49. Murphy M, et al. 2017. Eur J Immunol. 47:880. PubMed
  50. Schiller M, et al. 2021. Immunity. 54(5):1022-1036.e8. PubMed
  51. Jtte BB, et al. 2021. iScience. 24(8):102833. PubMed
  52. Chen X, et al. 2020. Andrologia. 52:e13823. PubMed
  53. Nagarajan D, et al. 2021. Immunol Cell Biol. 99:972. PubMed
  54. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  55. Cabrera-Mora M, et al. 2015. Infect Immun . 83: 3749-3761. PubMed
  56. Wang B, et al. 2022. Nat Commun. 13:3821. PubMed
  57. Ma J, et al. 2021. Curr Protoc. 1:e144. PubMed
  58. Samarchith P Kurup et al. 2019. Cell host & microbe. 25(4):565-577 . PubMed
  59. Fulham MA, et al. 2019. Am J Physiol Cell Physiol. 317:C687. PubMed
  60. Lv Z, et al. 2020. Oncoimmunology. 9:1747688. PubMed
  61. Hurrell BP, et al. 2019. Cell Rep. 29:4509. PubMed
  62. Chang Q, et al. 2020. Scand J Immunol. 92:e12877. PubMed
  63. He X, et al. 2021. Adv Sci (Weinh). 8:e2103023. PubMed
  64. Cong J et al. 2018. Cell metabolism. 28(2):243-255 . PubMed
  65. Wagle MV, et al. 2021. Nat Commun. 12:2782. PubMed
  66. Huang J, et al. 2015. Biochem Biophys Res Commun. 463: 551-556. PubMed
  67. Ni P, et al. 2014. Mol Immunol. 62:199. PubMed
  68. Gudgeon N, et al. 2022. Cell Rep. 40:111193. PubMed
  69. Tello-Lafoz M, et al. 2021. Immunity. 54(5):1037-1054.e7. PubMed
  70. Zuo S, et al. 2021. J Immunother Cancer. 9:. PubMed
  71. Hanna CC, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  72. Mulas F, et al. 2020. Cell Mol Immunol. . PubMed
  73. Stutz MD, et al. 2021. Immunity. 54(8):1758-1771.e7. PubMed
  74. Xu S, et al. 2021. Immunity. . PubMed
  75. Volberding PJ, et al. 2021. Cell Reports. 35(8):109160. PubMed
  76. Knocke S, et al. 2016. Cell Rep. 17:2234-2246. PubMed
  77. Ren Y, et al. 2022. J Immunother Cancer. 10:. PubMed
  78. Deczkowska A, et al. 2017. Nat Commun. 8:717. PubMed
  79. Wu J et al. 2019. Immunity. 50(5):1218-1231 . PubMed
  80. Chauveau L, et al. 2021. EMBO Rep. 22:e52447. PubMed
  81. Lu X, et al. 2015. J Immunol. 194:2011. PubMed
  82. Ding P, et al. 2022. Bone Res. 10:42. PubMed
  83. Vardhana SA, et al. 2020. Nat Immunol. 1.584722222. PubMed
  84. Mohamed E, et al. 2020. Immunity. 52(4):668-682.e7.. PubMed
  85. Akilov O, et al. 2007. J Leukoc Biol. 81:1188. PubMed
  86. Robles-Oteiza C, et al. 2021. Dis Model Mech. 14:. PubMed
  87. Stutz MD et al. 2018. Frontiers in immunology. 1.193055556 . PubMed
  88. Sjaastad FV, et al. 2020. Front Immunol. 11:1786. PubMed
  89. Wu J, et al. 2021. STAR Protoc. 2:101022. PubMed
  90. Fang Y, et al. 2021. J Clin Invest. 131:00:00. PubMed
  91. McCauley ME, et al. 2020. Nature. 585(7823):96-101. PubMed
  92. Baumann D, et al. 2020. Nat Commun. 1.969444444. PubMed
  93. Chen Y, et al. 2021. Nat Immunol. 22:996. PubMed
  94. Clemente–Casares X, et al. 2017. Immunity. 47:974. PubMed
  95. Bennion BG, et al. 2019. J Virol. 93. PubMed
  96. Baratin M, et al. 2017. Immunity. 47:349. PubMed
  97. Schaftenaar FH, et al. 2019. Sci Rep. 9:17391. PubMed
  98. Field CS, et al. 2020. Cell Metab. 31:422. PubMed
  99. Sun Y, et al. 2020. J Immunol. 205:2649. PubMed
  100. Neckermann P, et al. 2021. Front Immunol. 12:761214. PubMed
  101. Burger ML, et al. 2021. Cell. 184:4996. PubMed
  102. Huang WC, et al. 2020. Adv Mater. 32:e2005637. PubMed
  103. Chen L, et al. 2021. Theranostics. 11:6668. PubMed
  104. Montes de Oca M, et al. 2016. PLoS Pathog. 12: 1005398. PubMed
  105. Dahlin J, et al. 2012. J Immunol. 189:3869. PubMed
  106. Iyer RF, et al. 2022. PLoS Pathog. 18:e1010783. PubMed
  107. van Loon K, et al. 2022. Cancers (Basel). 14:. PubMed
  108. Ding Z, et al. 2017. Sci Rep. 10.1038/s41598-017-12488-z. PubMed
  109. Liu J, et al. 2016. Cancer Res . 76: 5288 - 5301. PubMed
  110. Charlton J, et al. 2015. PLoS One. 10:119200. PubMed
  111. Steinmann S, et al. 2020. Sci Rep. 1.160416667. PubMed
  112. Gardner A, et al. 2022. J Immunother Cancer. 10:. PubMed
  113. Rivera CA, et al. 2022. Immunity. 55:129. PubMed
  114. Li M, et al. 2020. J Immunother Cancer. 8:00. PubMed
  115. Zander R, et al. 2020. Immunity. 51(6):1028-1042.e4.. PubMed
  116. Brenner E, et al. 2020. Nat Commun. 11:1335. PubMed
  117. Li H, et al. 2021. Signal Transduct Target Ther. 6:389. PubMed
  118. C Khouili S, et al. 2020. Cell Rep. 33:108468. PubMed
  119. Olguín J, et al. 2015. Microbes Infect. 17: 586-595. PubMed
  120. Mendonça-Vieira LR, et al. 2021. Viruses. 13:. PubMed
  121. Zhou R, et al. 2022. EBioMedicine. 75:103762. PubMed
  122. Logan K Smith et al. 2018. Immunity. 48(2):299-312 . PubMed
  123. Djokić V, et al. 2019. Front Immunol. 9:2891. PubMed
  124. Darzianiazizi M, et al. 2020. Int J Mol Sci. 21:00. PubMed
  125. Asrat S, et al. 2014. PLoS Pathog. 10:1004229. PubMed
  126. Li B, Schmidt N 2016. PLoS One. 11: 0162427. PubMed
  127. Schenkel JM, et al. 2021. Immunity. 54:2338. PubMed
  128. Stone ET, et al. 2022. Cell Rep. 38:110388. PubMed
  129. Iberg CA, et al. 2022. Cell Rep. 39:110657. PubMed
  130. Lu R, et al. 2022. Scand J Immunol. 96:e13177. PubMed
  131. West HC, et al. 2022. Cell Rep. 39:110819. PubMed
  132. Blanas A, et al. 2022. iScience. 25:104719. PubMed
  133. Kang IH, et al. 2022. iScience. 25:104818. PubMed
  134. Balood M, et al. 2022. Nature. 611:405. PubMed
  135. Wei M, et al. 2022. Front Immunol. 13:1017574. PubMed
  136. Liu L, et al. 2022. Cell Biosci. 12:193. PubMed
  137. Huseni MA, et al. 2023. Cell Rep Med. 4:100878. PubMed
  138. Caslin HL, et al. 2023. Front Immunol. 13:984859. PubMed
  139. Cheng H, et al. 2023. Nat Metab. 5:314. PubMed
  140. Zander R, et al. 2022. Immunity. 55:475. PubMed
  141. Wight AE, et al. 2022. Proc Natl Acad Sci U S A. 119:e2200757119. PubMed
  142. Belk JA, et al. 2022. Cancer Cell. 40:768. PubMed
  143. Akhtar MN, et al. 2022. MBio. 13:e0330921. PubMed
  144. Pan Y, et al. 2023. Adv Sci (Weinh). 10:e2206792. PubMed
  145. Yu L, et al. 2023. Front Oncol. 13:1174713. PubMed
  146. Bhaskar A, et al. 2023. iScience. 26:106644. PubMed
  147. Xie J, et al. 2023. Mol Ther Oncolytics. 29:61. PubMed
  148. Liu W, et al. 2020. Mol Ther Oncolytics. 17:350. PubMed
  149. Wang Y, et al. 2021. Andrologia. 53:e14239. PubMed
  150. Wilfahrt D, et al. 2021. Elife. 10:. PubMed
  151. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  152. Wu T, et al. 2021. Mol Ther Oncolytics. 23:420. PubMed
  153. Zhou J, et al. 2019. Immunity. 50:403. PubMed
  154. Duan Q, et al. 2021. Front Cell Dev Biol. 9:761193. PubMed
  155. Chen L, et al. 2022. Mol Ther Oncolytics. 24:522. PubMed
  156. Liang S, et al. 2022. Acta Pharm Sin B. 12:2494. PubMed
  157. Harel M, et al. 2020. Cell. 179(1):236-250.e18.. PubMed
  158. Yang X, et al. 2021. Front Pharmacol. 12:771046. PubMed
  159. Lu Y, et al. 2019. Int J Mol Med. 43:2398. PubMed
  160. Álvaro de Mingo Pulido et al. 2018. Cancer cell. 33(1):60-74 . PubMed
  161. Wabitsch S, et al. 2021. STAR Protoc. 2:100517. PubMed
  162. Liu Q, et al. 2021. Cell Death Dis. 12:240. PubMed
  163. Liu X, et al. 2020. Nature. . PubMed
  164. Haque M, et al. 2021. STAR Protoc. 2:100264. PubMed
  165. Wu J, et al. 2020. Sci Adv. 6:eaba3458. PubMed
  166. Suzuki M, et al. 2021. Sci Adv. 7:. PubMed
  167. Chen D, et al. 2018. Nat Commun. 9:873. PubMed
  168. Murphy M, et al. 2017. Eur J Immunol. 47:880. PubMed
  169. Schiller M, et al. 2021. Immunity. 54(5):1022-1036.e8. PubMed
  170. Jtte BB, et al. 2021. iScience. 24(8):102833. PubMed
  171. Chen X, et al. 2020. Andrologia. 52:e13823. PubMed
  172. Nagarajan D, et al. 2021. Immunol Cell Biol. 99:972. PubMed
  173. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  174. Cabrera-Mora M, et al. 2015. Infect Immun . 83: 3749-3761. PubMed
  175. Wang B, et al. 2022. Nat Commun. 13:3821. PubMed
  176. Ma J, et al. 2021. Curr Protoc. 1:e144. PubMed
  177. Samarchith P Kurup et al. 2019. Cell host & microbe. 25(4):565-577 . PubMed
  178. Fulham MA, et al. 2019. Am J Physiol Cell Physiol. 317:C687. PubMed
  179. Lv Z, et al. 2020. Oncoimmunology. 9:1747688. PubMed
  180. Hurrell BP, et al. 2019. Cell Rep. 29:4509. PubMed
  181. Chang Q, et al. 2020. Scand J Immunol. 92:e12877. PubMed
  182. He X, et al. 2021. Adv Sci (Weinh). 8:e2103023. PubMed
  183. Cong J et al. 2018. Cell metabolism. 28(2):243-255 . PubMed
  184. Wagle MV, et al. 2021. Nat Commun. 12:2782. PubMed
  185. Huang J, et al. 2015. Biochem Biophys Res Commun. 463: 551-556. PubMed
  186. Ni P, et al. 2014. Mol Immunol. 62:199. PubMed
  187. Gudgeon N, et al. 2022. Cell Rep. 40:111193. PubMed
  188. Tello-Lafoz M, et al. 2021. Immunity. 54(5):1037-1054.e7. PubMed
  189. Zuo S, et al. 2021. J Immunother Cancer. 9:. PubMed
  190. Hanna CC, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  191. Mulas F, et al. 2020. Cell Mol Immunol. . PubMed
  192. Stutz MD, et al. 2021. Immunity. 54(8):1758-1771.e7. PubMed
  193. Xu S, et al. 2021. Immunity. . PubMed
  194. Volberding PJ, et al. 2021. Cell Reports. 35(8):109160. PubMed
  195. Knocke S, et al. 2016. Cell Rep. 17:2234-2246. PubMed
  196. Ren Y, et al. 2022. J Immunother Cancer. 10:. PubMed
  197. Deczkowska A, et al. 2017. Nat Commun. 8:717. PubMed
  198. Wu J et al. 2019. Immunity. 50(5):1218-1231 . PubMed
  199. Chauveau L, et al. 2021. EMBO Rep. 22:e52447. PubMed
  200. Lu X, et al. 2015. J Immunol. 194:2011. PubMed
  201. Ding P, et al. 2022. Bone Res. 10:42. PubMed
  202. Vardhana SA, et al. 2020. Nat Immunol. 1.584722222. PubMed
  203. Mohamed E, et al. 2020. Immunity. 52(4):668-682.e7.. PubMed
  204. Akilov O, et al. 2007. J Leukoc Biol. 81:1188. PubMed
  205. Robles-Oteiza C, et al. 2021. Dis Model Mech. 14:. PubMed
  206. Stutz MD et al. 2018. Frontiers in immunology. 1.193055556 . PubMed
  207. Sjaastad FV, et al. 2020. Front Immunol. 11:1786. PubMed
  208. Wu J, et al. 2021. STAR Protoc. 2:101022. PubMed
  209. Fang Y, et al. 2021. J Clin Invest. 131:00:00. PubMed
  210. McCauley ME, et al. 2020. Nature. 585(7823):96-101. PubMed
  211. Baumann D, et al. 2020. Nat Commun. 1.969444444. PubMed
  212. Chen Y, et al. 2021. Nat Immunol. 22:996. PubMed
  213. Clemente–Casares X, et al. 2017. Immunity. 47:974. PubMed
  214. Bennion BG, et al. 2019. J Virol. 93. PubMed
  215. Baratin M, et al. 2017. Immunity. 47:349. PubMed
  216. Schaftenaar FH, et al. 2019. Sci Rep. 9:17391. PubMed
  217. Field CS, et al. 2020. Cell Metab. 31:422. PubMed
  218. Sun Y, et al. 2020. J Immunol. 205:2649. PubMed
  219. Neckermann P, et al. 2021. Front Immunol. 12:761214. PubMed
  220. Burger ML, et al. 2021. Cell. 184:4996. PubMed
  221. Huang WC, et al. 2020. Adv Mater. 32:e2005637. PubMed
  222. Chen L, et al. 2021. Theranostics. 11:6668. PubMed
  223. Montes de Oca M, et al. 2016. PLoS Pathog. 12: 1005398. PubMed
  224. Dahlin J, et al. 2012. J Immunol. 189:3869. PubMed
  225. Iyer RF, et al. 2022. PLoS Pathog. 18:e1010783. PubMed
  226. van Loon K, et al. 2022. Cancers (Basel). 14:. PubMed
  227. Ding Z, et al. 2017. Sci Rep. 10.1038/s41598-017-12488-z. PubMed
  228. Liu J, et al. 2016. Cancer Res . 76: 5288 - 5301. PubMed
  229. Charlton J, et al. 2015. PLoS One. 10:119200. PubMed
  230. Steinmann S, et al. 2020. Sci Rep. 1.160416667. PubMed
  231. Gardner A, et al. 2022. J Immunother Cancer. 10:. PubMed
  232. Rivera CA, et al. 2022. Immunity. 55:129. PubMed
  233. Li M, et al. 2020. J Immunother Cancer. 8:00. PubMed
  234. Zander R, et al. 2020. Immunity. 51(6):1028-1042.e4.. PubMed
  235. Brenner E, et al. 2020. Nat Commun. 11:1335. PubMed
  236. Li H, et al. 2021. Signal Transduct Target Ther. 6:389. PubMed
  237. C Khouili S, et al. 2020. Cell Rep. 33:108468. PubMed
  238. Olguín J, et al. 2015. Microbes Infect. 17: 586-595. PubMed
RRID
AB_315426 (BioLegend Cat. No. 506305)
AB_315427 (BioLegend Cat. No. 506306)

Antigen Details

Structure
TNF superfamily; dimer/trimer; 17.5-150 kD (Mammalian)
Bioactivity
Paracrine/endocrine mediator of inflammatory and immune functions; selectively cytotoxic for transformed cells; endothelial cell alterations; chemoattractant
Cell Sources
Activated monocytes, neutrophils, macrophages, T cells, B cells, NK cells, LAK cells
Cell Targets
Monocytes, neutrophils, macrophages, T cells, fibroblasts, endothelial cells, osteoclasts, adipocytes, astroglia, microglia
Receptors
TNFRSF1A (TNF-R1, CD120a, TNFR-p60 Type β, p55); TNFRSF1B (TNF-R2, CD120b, TNFR-p80 Type A, p75)
Cell Type
Tregs
Biology Area
Immunology, Innate Immunity
Molecular Family
Cytokines/Chemokines
Antigen References

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego.
2. Beutler B, et al. 1988. Annu. Rev. Biochem. 57:505.
3. Beutler B, et al. 1989. Annu. Rev. Immunol. 7:625.
4. Tracey K, et al. 1993. Crit. Care Med. 21:S415.

Regulation
Processed by TACE for secretion; upregulated by interferons, IL-2, GM-CSF, substance P, bradykinin, PAF, immune complexes, and cyclooxygenase; downregulated by IL-6, TGF-β, vitamin D3, prostaglandin E2, and PAF antagonists
Gene ID
21926 View all products for this Gene ID
UniProt
View information about TNF-alpha on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.

Other Formats

View All TNF-α Reagents Request Custom Conjugation
Description Clone Applications
Brilliant Violet 785™ anti-mouse TNF-α MP6-XT22 ICFC
APC/Cyanine7 anti-mouse TNF-α MP6-XT22 ICFC
PE/Dazzle™ 594 anti-mouse TNF-α MP6-XT22 ICFC
Brilliant Violet 711™ anti-mouse TNF-α MP6-XT22 ICFC
Brilliant Violet 750™ anti-mouse TNF-α MP6-XT22 ICFC
GoInVivo™ Purified anti-mouse TNF-α MP6-XT22 ELISA,ICFC,CyTOF®,ICC,IHC-F,WB,Neut
APC anti-mouse TNF-α MP6-XT22 ICFC
FITC anti-mouse TNF-α MP6-XT22 ICFC
PE anti-mouse TNF-α MP6-XT22 ICFC
Purified anti-mouse TNF-α MP6-XT22 ELISA,CyTOF®,ICC,ICFC,IHC-F,WB
Biotin anti-mouse TNF-α MP6-XT22 ELISA Detection,ELISPOT Detection,ICFC
Alexa Fluor® 488 anti-mouse TNF-α MP6-XT22 ICFC
Alexa Fluor® 647 anti-mouse TNF-α MP6-XT22 ICFC
Pacific Blue™ anti-mouse TNF-α MP6-XT22 ICFC
PerCP/Cyanine5.5 anti-mouse TNF-α MP6-XT22 ICFC
PE/Cyanine7 anti-mouse TNF-α MP6-XT22 ICFC
Brilliant Violet 421™ anti-mouse TNF-α MP6-XT22 ICFC
Ultra-LEAF™ Purified anti-mouse TNF-α MP6-XT22 ELISA,CyTOF®,ICC,ICFC,IHC-F,WB,Neut
Brilliant Violet 605™ anti-mouse TNF-α MP6-XT22 ICFC
Brilliant Violet 650™ anti-mouse TNF-α MP6-XT22 ICFC
Alexa Fluor® 700 anti-mouse TNF-α MP6-XT22 ICFC
Purified anti-mouse TNF-α (Maxpar® Ready) MP6-XT22 ELISA,CyTOF®
Brilliant Violet 510™ anti-mouse TNF-α MP6-XT22 ICFC
Spark NIR™ 685 anti-mouse TNF-α MP6-XT22 ICFC
TotalSeq™-C1529 anti-mouse TNF-α Antibody MP6-XT22 ICPG
TotalSeq™-B1529 anti-mouse TNF-α Antibody MP6-XT22 ICPG
Go To Top Version: 2    Revision Date: 10/14/2013

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

Pricing & Availability
Clone
MP6-XT22 (See other available formats)
Regulatory Status
RUO
Other Names
Tumor necrosis factor-α, Cachectin, Necrosin, Macrophage cytotoxic factor (MCF), Differentiation inducing factor (DIF), TNFSF-2, TNF-a, TNF-alpha
Isotype
Rat IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
MP6-XT22_PE_TNF-a_Antibody_FC_1_100913
PMA + Ionomycin-stimulated C57BL/6 mouse splenocytes (in the presence of monensin) were stained with CD3 APC, fixed, permeabilized and then stained with TNF-α (clone MP6-XT22) PE (top) or rat IgG1, κ PE isotype control (bottom).
  • MP6-XT22_PE_TNF-a_Antibody_FC_1_100913
    PMA + Ionomycin-stimulated C57BL/6 mouse splenocytes (in the presence of monensin) were stained with CD3 APC, fixed, permeabilized and then stained with TNF-α (clone MP6-XT22) PE (top) or rat IgG1, κ PE isotype control (bottom).
  • MP6-XT22_PE_TNF-a_Antibody_FC_2_101413
Compare all formats See PE spectral data
Cat # Size Price Quantity Check Availability Save
506305 25 µg DKK404
Check Availability


Need larger quantities of this item?
Request Bulk Quote
506306 100 µg DKK1414
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

TNF-α is secreted by macrophages, monocytes, neutrophils, T-cells, and NK-cells. Many transformed cell lines also secrete TNF-α. Monomeric mouse TNF-α is a 156 amino acid protein (N-glycosylated) with a reported molecular weight of 17.5 kD. TNF-α forms multimeric complexes; stable trimers are most common in solution. A 26 kD membrane form of TNF-α has also been described. TNF-α binding to surface receptors elicits a wide array of biologic activities including: cytolysis and cytostasis of many tumor cell lines in vitro, hemorrhagic necrosis of tumors in vivo, increased fibroblast proliferation, and enhanced chemotaxis and phagocytosis in neutrophils.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
E. coli-expressed, recombinant mouse TNF-α
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

ICFC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

ELISA Capture: The purified MP6-XT22 antibody is useful as the capture antibody in a sandwich ELISA when used in conjunction with the biotinylated Poly5160 antibody (Cat. No. 516003) as the detection antibody and recombinant mouse TNF-α (Cat. No. 575209) as the standard.
Flow Cytometry6,11,12:The fluorochrome-labeled MP6-XT22 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify TNF-a-producing cells within mixed cell populations.
Neutralization1,5,10,16,17:The MP6-XT22 antibody can neutralize the bioactivity of natural or recombinant TNF-α. The LEAF™ purified antibody (Endotoxin < 0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse TNF-α bioactivity in vivo and in vitro(Cat. No. 506310). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 506332) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).
Additional reported applications (for the relevant formats) include: Western blotting, immunohistochemical staining of paraformaldehyde-fixed, saponin-treated frozen tissue sections7-9 in vivo detection5, immunofluorescence, and immunocytochemistry.
Note: For testing mouse TNF-α in serum, plasma or supernatant, BioLegend's ELISA Max™ Sets (Cat. No. 430901) are specially developed and recommended.

Application References
  1. Abrams J, et al. 1992. Immunol. Rev. 127:5. (Neut)
  2. Abrams J, et al. 1995. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.20
  3. Mo X, et al. 1995. J. Virol. 69:1288.
  4. Sarawar S, et al. 1994. J. Immunol. 153:1246.
  5. Via C, et al. 2001. J. Immunol. 167:6821. (Neut)
  6. Infante-Duarte C, et al. 2000 J. Immunol. 165:6107. (FC)
  7. Jacobs M, et al. 2000. Immunology 100:494. (IHC)
  8. Marinova-Mutachieva L, et al. 1997. Clin. Exp. Immunol. 107:507. (IHC)
  9. Williams RO, et al. 2000. J. Immunol. 165:7240. (IHC)
  10. Scanga CA, et al. 1999. Infect. Immun. 67:4531. (Neut)
  11. Akilov OE, et al. 2007. J. Leukoc. Biol. 2007;10.1189/jlb.0706439. (FC)
  12. Lawson BR, et al. 2007. J. Immunol. 178:5366. (FC)
  13. Patole PS, et al. 2005. J. Am. Soc. Nephrol. 16:3273. PubMed
  14. Wu S, et al. 2005. Neurosci Lett. 394:158. PubMed
  15. Carlson MJ, et al. 2009. Blood 113:1365. PubMed
  16. Shivakumar P, et al. 2017. JCI Insight. 2:e88747 1. PubMed
  17. Kearney CJ, et al. 2017. Cell Death Differ. 10.1038/cdd.2017.94. PubMed
Product Citations
  1. Mendonça-Vieira LR, et al. 2021. Viruses. 13:. PubMed
  2. Zhou R, et al. 2022. EBioMedicine. 75:103762. PubMed
  3. Logan K Smith et al. 2018. Immunity. 48(2):299-312 . PubMed
  4. Djokić V, et al. 2019. Front Immunol. 9:2891. PubMed
  5. Darzianiazizi M, et al. 2020. Int J Mol Sci. 21:00. PubMed
  6. Asrat S, et al. 2014. PLoS Pathog. 10:1004229. PubMed
  7. Li B, Schmidt N 2016. PLoS One. 11: 0162427. PubMed
  8. Schenkel JM, et al. 2021. Immunity. 54:2338. PubMed
  9. Stone ET, et al. 2022. Cell Rep. 38:110388. PubMed
  10. Iberg CA, et al. 2022. Cell Rep. 39:110657. PubMed
  11. Lu R, et al. 2022. Scand J Immunol. 96:e13177. PubMed
  12. West HC, et al. 2022. Cell Rep. 39:110819. PubMed
  13. Blanas A, et al. 2022. iScience. 25:104719. PubMed
  14. Kang IH, et al. 2022. iScience. 25:104818. PubMed
  15. Balood M, et al. 2022. Nature. 611:405. PubMed
  16. Wei M, et al. 2022. Front Immunol. 13:1017574. PubMed
  17. Liu L, et al. 2022. Cell Biosci. 12:193. PubMed
  18. Huseni MA, et al. 2023. Cell Rep Med. 4:100878. PubMed
  19. Caslin HL, et al. 2023. Front Immunol. 13:984859. PubMed
  20. Cheng H, et al. 2023. Nat Metab. 5:314. PubMed
  21. Zander R, et al. 2022. Immunity. 55:475. PubMed
  22. Wight AE, et al. 2022. Proc Natl Acad Sci U S A. 119:e2200757119. PubMed
  23. Belk JA, et al. 2022. Cancer Cell. 40:768. PubMed
  24. Akhtar MN, et al. 2022. MBio. 13:e0330921. PubMed
  25. Pan Y, et al. 2023. Adv Sci (Weinh). 10:e2206792. PubMed
  26. Yu L, et al. 2023. Front Oncol. 13:1174713. PubMed
  27. Bhaskar A, et al. 2023. iScience. 26:106644. PubMed
  28. Xie J, et al. 2023. Mol Ther Oncolytics. 29:61. PubMed
  29. Liu W, et al. 2020. Mol Ther Oncolytics. 17:350. PubMed
  30. Wang Y, et al. 2021. Andrologia. 53:e14239. PubMed
  31. Wilfahrt D, et al. 2021. Elife. 10:. PubMed
  32. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  33. Wu T, et al. 2021. Mol Ther Oncolytics. 23:420. PubMed
  34. Zhou J, et al. 2019. Immunity. 50:403. PubMed
  35. Duan Q, et al. 2021. Front Cell Dev Biol. 9:761193. PubMed
  36. Chen L, et al. 2022. Mol Ther Oncolytics. 24:522. PubMed
  37. Liang S, et al. 2022. Acta Pharm Sin B. 12:2494. PubMed
  38. Harel M, et al. 2020. Cell. 179(1):236-250.e18.. PubMed
  39. Yang X, et al. 2021. Front Pharmacol. 12:771046. PubMed
  40. Lu Y, et al. 2019. Int J Mol Med. 43:2398. PubMed
  41. Álvaro de Mingo Pulido et al. 2018. Cancer cell. 33(1):60-74 . PubMed
  42. Wabitsch S, et al. 2021. STAR Protoc. 2:100517. PubMed
  43. Liu Q, et al. 2021. Cell Death Dis. 12:240. PubMed
  44. Liu X, et al. 2020. Nature. . PubMed
  45. Haque M, et al. 2021. STAR Protoc. 2:100264. PubMed
  46. Wu J, et al. 2020. Sci Adv. 6:eaba3458. PubMed
  47. Suzuki M, et al. 2021. Sci Adv. 7:. PubMed
  48. Chen D, et al. 2018. Nat Commun. 9:873. PubMed
  49. Murphy M, et al. 2017. Eur J Immunol. 47:880. PubMed
  50. Schiller M, et al. 2021. Immunity. 54(5):1022-1036.e8. PubMed
  51. Jtte BB, et al. 2021. iScience. 24(8):102833. PubMed
  52. Chen X, et al. 2020. Andrologia. 52:e13823. PubMed
  53. Nagarajan D, et al. 2021. Immunol Cell Biol. 99:972. PubMed
  54. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  55. Cabrera-Mora M, et al. 2015. Infect Immun . 83: 3749-3761. PubMed
  56. Wang B, et al. 2022. Nat Commun. 13:3821. PubMed
  57. Ma J, et al. 2021. Curr Protoc. 1:e144. PubMed
  58. Samarchith P Kurup et al. 2019. Cell host & microbe. 25(4):565-577 . PubMed
  59. Fulham MA, et al. 2019. Am J Physiol Cell Physiol. 317:C687. PubMed
  60. Lv Z, et al. 2020. Oncoimmunology. 9:1747688. PubMed
  61. Hurrell BP, et al. 2019. Cell Rep. 29:4509. PubMed
  62. Chang Q, et al. 2020. Scand J Immunol. 92:e12877. PubMed
  63. He X, et al. 2021. Adv Sci (Weinh). 8:e2103023. PubMed
  64. Cong J et al. 2018. Cell metabolism. 28(2):243-255 . PubMed
  65. Wagle MV, et al. 2021. Nat Commun. 12:2782. PubMed
  66. Huang J, et al. 2015. Biochem Biophys Res Commun. 463: 551-556. PubMed
  67. Ni P, et al. 2014. Mol Immunol. 62:199. PubMed
  68. Gudgeon N, et al. 2022. Cell Rep. 40:111193. PubMed
  69. Tello-Lafoz M, et al. 2021. Immunity. 54(5):1037-1054.e7. PubMed
  70. Zuo S, et al. 2021. J Immunother Cancer. 9:. PubMed
  71. Hanna CC, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  72. Mulas F, et al. 2020. Cell Mol Immunol. . PubMed
  73. Stutz MD, et al. 2021. Immunity. 54(8):1758-1771.e7. PubMed
  74. Xu S, et al. 2021. Immunity. . PubMed
  75. Volberding PJ, et al. 2021. Cell Reports. 35(8):109160. PubMed
  76. Knocke S, et al. 2016. Cell Rep. 17:2234-2246. PubMed
  77. Ren Y, et al. 2022. J Immunother Cancer. 10:. PubMed
  78. Deczkowska A, et al. 2017. Nat Commun. 8:717. PubMed
  79. Wu J et al. 2019. Immunity. 50(5):1218-1231 . PubMed
  80. Chauveau L, et al. 2021. EMBO Rep. 22:e52447. PubMed
  81. Lu X, et al. 2015. J Immunol. 194:2011. PubMed
  82. Ding P, et al. 2022. Bone Res. 10:42. PubMed
  83. Vardhana SA, et al. 2020. Nat Immunol. 1.584722222. PubMed
  84. Mohamed E, et al. 2020. Immunity. 52(4):668-682.e7.. PubMed
  85. Akilov O, et al. 2007. J Leukoc Biol. 81:1188. PubMed
  86. Robles-Oteiza C, et al. 2021. Dis Model Mech. 14:. PubMed
  87. Stutz MD et al. 2018. Frontiers in immunology. 1.193055556 . PubMed
  88. Sjaastad FV, et al. 2020. Front Immunol. 11:1786. PubMed
  89. Wu J, et al. 2021. STAR Protoc. 2:101022. PubMed
  90. Fang Y, et al. 2021. J Clin Invest. 131:00:00. PubMed
  91. McCauley ME, et al. 2020. Nature. 585(7823):96-101. PubMed
  92. Baumann D, et al. 2020. Nat Commun. 1.969444444. PubMed
  93. Chen Y, et al. 2021. Nat Immunol. 22:996. PubMed
  94. Clemente–Casares X, et al. 2017. Immunity. 47:974. PubMed
  95. Bennion BG, et al. 2019. J Virol. 93. PubMed
  96. Baratin M, et al. 2017. Immunity. 47:349. PubMed
  97. Schaftenaar FH, et al. 2019. Sci Rep. 9:17391. PubMed
  98. Field CS, et al. 2020. Cell Metab. 31:422. PubMed
  99. Sun Y, et al. 2020. J Immunol. 205:2649. PubMed
  100. Neckermann P, et al. 2021. Front Immunol. 12:761214. PubMed
  101. Burger ML, et al. 2021. Cell. 184:4996. PubMed
  102. Huang WC, et al. 2020. Adv Mater. 32:e2005637. PubMed
  103. Chen L, et al. 2021. Theranostics. 11:6668. PubMed
  104. Montes de Oca M, et al. 2016. PLoS Pathog. 12: 1005398. PubMed
  105. Dahlin J, et al. 2012. J Immunol. 189:3869. PubMed
  106. Iyer RF, et al. 2022. PLoS Pathog. 18:e1010783. PubMed
  107. van Loon K, et al. 2022. Cancers (Basel). 14:. PubMed
  108. Ding Z, et al. 2017. Sci Rep. 10.1038/s41598-017-12488-z. PubMed
  109. Liu J, et al. 2016. Cancer Res . 76: 5288 - 5301. PubMed
  110. Charlton J, et al. 2015. PLoS One. 10:119200. PubMed
  111. Steinmann S, et al. 2020. Sci Rep. 1.160416667. PubMed
  112. Gardner A, et al. 2022. J Immunother Cancer. 10:. PubMed
  113. Rivera CA, et al. 2022. Immunity. 55:129. PubMed
  114. Li M, et al. 2020. J Immunother Cancer. 8:00. PubMed
  115. Zander R, et al. 2020. Immunity. 51(6):1028-1042.e4.. PubMed
  116. Brenner E, et al. 2020. Nat Commun. 11:1335. PubMed
  117. Li H, et al. 2021. Signal Transduct Target Ther. 6:389. PubMed
  118. C Khouili S, et al. 2020. Cell Rep. 33:108468. PubMed
  119. Olguín J, et al. 2015. Microbes Infect. 17: 586-595. PubMed
  120. Mendonça-Vieira LR, et al. 2021. Viruses. 13:. PubMed
  121. Zhou R, et al. 2022. EBioMedicine. 75:103762. PubMed
  122. Logan K Smith et al. 2018. Immunity. 48(2):299-312 . PubMed
  123. Djokić V, et al. 2019. Front Immunol. 9:2891. PubMed
  124. Darzianiazizi M, et al. 2020. Int J Mol Sci. 21:00. PubMed
  125. Asrat S, et al. 2014. PLoS Pathog. 10:1004229. PubMed
  126. Li B, Schmidt N 2016. PLoS One. 11: 0162427. PubMed
  127. Schenkel JM, et al. 2021. Immunity. 54:2338. PubMed
  128. Stone ET, et al. 2022. Cell Rep. 38:110388. PubMed
  129. Iberg CA, et al. 2022. Cell Rep. 39:110657. PubMed
  130. Lu R, et al. 2022. Scand J Immunol. 96:e13177. PubMed
  131. West HC, et al. 2022. Cell Rep. 39:110819. PubMed
  132. Blanas A, et al. 2022. iScience. 25:104719. PubMed
  133. Kang IH, et al. 2022. iScience. 25:104818. PubMed
  134. Balood M, et al. 2022. Nature. 611:405. PubMed
  135. Wei M, et al. 2022. Front Immunol. 13:1017574. PubMed
  136. Liu L, et al. 2022. Cell Biosci. 12:193. PubMed
  137. Huseni MA, et al. 2023. Cell Rep Med. 4:100878. PubMed
  138. Caslin HL, et al. 2023. Front Immunol. 13:984859. PubMed
  139. Cheng H, et al. 2023. Nat Metab. 5:314. PubMed
  140. Zander R, et al. 2022. Immunity. 55:475. PubMed
  141. Wight AE, et al. 2022. Proc Natl Acad Sci U S A. 119:e2200757119. PubMed
  142. Belk JA, et al. 2022. Cancer Cell. 40:768. PubMed
  143. Akhtar MN, et al. 2022. MBio. 13:e0330921. PubMed
  144. Pan Y, et al. 2023. Adv Sci (Weinh). 10:e2206792. PubMed
  145. Yu L, et al. 2023. Front Oncol. 13:1174713. PubMed
  146. Bhaskar A, et al. 2023. iScience. 26:106644. PubMed
  147. Xie J, et al. 2023. Mol Ther Oncolytics. 29:61. PubMed
  148. Liu W, et al. 2020. Mol Ther Oncolytics. 17:350. PubMed
  149. Wang Y, et al. 2021. Andrologia. 53:e14239. PubMed
  150. Wilfahrt D, et al. 2021. Elife. 10:. PubMed
  151. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  152. Wu T, et al. 2021. Mol Ther Oncolytics. 23:420. PubMed
  153. Zhou J, et al. 2019. Immunity. 50:403. PubMed
  154. Duan Q, et al. 2021. Front Cell Dev Biol. 9:761193. PubMed
  155. Chen L, et al. 2022. Mol Ther Oncolytics. 24:522. PubMed
  156. Liang S, et al. 2022. Acta Pharm Sin B. 12:2494. PubMed
  157. Harel M, et al. 2020. Cell. 179(1):236-250.e18.. PubMed
  158. Yang X, et al. 2021. Front Pharmacol. 12:771046. PubMed
  159. Lu Y, et al. 2019. Int J Mol Med. 43:2398. PubMed
  160. Álvaro de Mingo Pulido et al. 2018. Cancer cell. 33(1):60-74 . PubMed
  161. Wabitsch S, et al. 2021. STAR Protoc. 2:100517. PubMed
  162. Liu Q, et al. 2021. Cell Death Dis. 12:240. PubMed
  163. Liu X, et al. 2020. Nature. . PubMed
  164. Haque M, et al. 2021. STAR Protoc. 2:100264. PubMed
  165. Wu J, et al. 2020. Sci Adv. 6:eaba3458. PubMed
  166. Suzuki M, et al. 2021. Sci Adv. 7:. PubMed
  167. Chen D, et al. 2018. Nat Commun. 9:873. PubMed
  168. Murphy M, et al. 2017. Eur J Immunol. 47:880. PubMed
  169. Schiller M, et al. 2021. Immunity. 54(5):1022-1036.e8. PubMed
  170. Jtte BB, et al. 2021. iScience. 24(8):102833. PubMed
  171. Chen X, et al. 2020. Andrologia. 52:e13823. PubMed
  172. Nagarajan D, et al. 2021. Immunol Cell Biol. 99:972. PubMed
  173. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  174. Cabrera-Mora M, et al. 2015. Infect Immun . 83: 3749-3761. PubMed
  175. Wang B, et al. 2022. Nat Commun. 13:3821. PubMed
  176. Ma J, et al. 2021. Curr Protoc. 1:e144. PubMed
  177. Samarchith P Kurup et al. 2019. Cell host & microbe. 25(4):565-577 . PubMed
  178. Fulham MA, et al. 2019. Am J Physiol Cell Physiol. 317:C687. PubMed
  179. Lv Z, et al. 2020. Oncoimmunology. 9:1747688. PubMed
  180. Hurrell BP, et al. 2019. Cell Rep. 29:4509. PubMed
  181. Chang Q, et al. 2020. Scand J Immunol. 92:e12877. PubMed
  182. He X, et al. 2021. Adv Sci (Weinh). 8:e2103023. PubMed
  183. Cong J et al. 2018. Cell metabolism. 28(2):243-255 . PubMed
  184. Wagle MV, et al. 2021. Nat Commun. 12:2782. PubMed
  185. Huang J, et al. 2015. Biochem Biophys Res Commun. 463: 551-556. PubMed
  186. Ni P, et al. 2014. Mol Immunol. 62:199. PubMed
  187. Gudgeon N, et al. 2022. Cell Rep. 40:111193. PubMed
  188. Tello-Lafoz M, et al. 2021. Immunity. 54(5):1037-1054.e7. PubMed
  189. Zuo S, et al. 2021. J Immunother Cancer. 9:. PubMed
  190. Hanna CC, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  191. Mulas F, et al. 2020. Cell Mol Immunol. . PubMed
  192. Stutz MD, et al. 2021. Immunity. 54(8):1758-1771.e7. PubMed
  193. Xu S, et al. 2021. Immunity. . PubMed
  194. Volberding PJ, et al. 2021. Cell Reports. 35(8):109160. PubMed
  195. Knocke S, et al. 2016. Cell Rep. 17:2234-2246. PubMed
  196. Ren Y, et al. 2022. J Immunother Cancer. 10:. PubMed
  197. Deczkowska A, et al. 2017. Nat Commun. 8:717. PubMed
  198. Wu J et al. 2019. Immunity. 50(5):1218-1231 . PubMed
  199. Chauveau L, et al. 2021. EMBO Rep. 22:e52447. PubMed
  200. Lu X, et al. 2015. J Immunol. 194:2011. PubMed
  201. Ding P, et al. 2022. Bone Res. 10:42. PubMed
  202. Vardhana SA, et al. 2020. Nat Immunol. 1.584722222. PubMed
  203. Mohamed E, et al. 2020. Immunity. 52(4):668-682.e7.. PubMed
  204. Akilov O, et al. 2007. J Leukoc Biol. 81:1188. PubMed
  205. Robles-Oteiza C, et al. 2021. Dis Model Mech. 14:. PubMed
  206. Stutz MD et al. 2018. Frontiers in immunology. 1.193055556 . PubMed
  207. Sjaastad FV, et al. 2020. Front Immunol. 11:1786. PubMed
  208. Wu J, et al. 2021. STAR Protoc. 2:101022. PubMed
  209. Fang Y, et al. 2021. J Clin Invest. 131:00:00. PubMed
  210. McCauley ME, et al. 2020. Nature. 585(7823):96-101. PubMed
  211. Baumann D, et al. 2020. Nat Commun. 1.969444444. PubMed
  212. Chen Y, et al. 2021. Nat Immunol. 22:996. PubMed
  213. Clemente–Casares X, et al. 2017. Immunity. 47:974. PubMed
  214. Bennion BG, et al. 2019. J Virol. 93. PubMed
  215. Baratin M, et al. 2017. Immunity. 47:349. PubMed
  216. Schaftenaar FH, et al. 2019. Sci Rep. 9:17391. PubMed
  217. Field CS, et al. 2020. Cell Metab. 31:422. PubMed
  218. Sun Y, et al. 2020. J Immunol. 205:2649. PubMed
  219. Neckermann P, et al. 2021. Front Immunol. 12:761214. PubMed
  220. Burger ML, et al. 2021. Cell. 184:4996. PubMed
  221. Huang WC, et al. 2020. Adv Mater. 32:e2005637. PubMed
  222. Chen L, et al. 2021. Theranostics. 11:6668. PubMed
  223. Montes de Oca M, et al. 2016. PLoS Pathog. 12: 1005398. PubMed
  224. Dahlin J, et al. 2012. J Immunol. 189:3869. PubMed
  225. Iyer RF, et al. 2022. PLoS Pathog. 18:e1010783. PubMed
  226. van Loon K, et al. 2022. Cancers (Basel). 14:. PubMed
  227. Ding Z, et al. 2017. Sci Rep. 10.1038/s41598-017-12488-z. PubMed
  228. Liu J, et al. 2016. Cancer Res . 76: 5288 - 5301. PubMed
  229. Charlton J, et al. 2015. PLoS One. 10:119200. PubMed
  230. Steinmann S, et al. 2020. Sci Rep. 1.160416667. PubMed
  231. Gardner A, et al. 2022. J Immunother Cancer. 10:. PubMed
  232. Rivera CA, et al. 2022. Immunity. 55:129. PubMed
  233. Li M, et al. 2020. J Immunother Cancer. 8:00. PubMed
  234. Zander R, et al. 2020. Immunity. 51(6):1028-1042.e4.. PubMed
  235. Brenner E, et al. 2020. Nat Commun. 11:1335. PubMed
  236. Li H, et al. 2021. Signal Transduct Target Ther. 6:389. PubMed
  237. C Khouili S, et al. 2020. Cell Rep. 33:108468. PubMed
  238. Olguín J, et al. 2015. Microbes Infect. 17: 586-595. PubMed
RRID
AB_315426 (BioLegend Cat. No. 506305)
AB_315427 (BioLegend Cat. No. 506306)

Antigen Details

Structure
TNF superfamily; dimer/trimer; 17.5-150 kD (Mammalian)
Bioactivity
Paracrine/endocrine mediator of inflammatory and immune functions; selectively cytotoxic for transformed cells; endothelial cell alterations; chemoattractant
Cell Sources
Activated monocytes, neutrophils, macrophages, T cells, B cells, NK cells, LAK cells
Cell Targets
Monocytes, neutrophils, macrophages, T cells, fibroblasts, endothelial cells, osteoclasts, adipocytes, astroglia, microglia
Receptors
TNFRSF1A (TNF-R1, CD120a, TNFR-p60 Type β, p55); TNFRSF1B (TNF-R2, CD120b, TNFR-p80 Type A, p75)
Cell Type
Tregs
Biology Area
Immunology, Innate Immunity
Molecular Family
Cytokines/Chemokines
Antigen References

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego.
2. Beutler B, et al. 1988. Annu. Rev. Biochem. 57:505.
3. Beutler B, et al. 1989. Annu. Rev. Immunol. 7:625.
4. Tracey K, et al. 1993. Crit. Care Med. 21:S415.

Regulation
Processed by TACE for secretion; upregulated by interferons, IL-2, GM-CSF, substance P, bradykinin, PAF, immune complexes, and cyclooxygenase; downregulated by IL-6, TGF-β, vitamin D3, prostaglandin E2, and PAF antagonists
Gene ID
21926 View all products for this Gene ID
UniProt
View information about TNF-alpha on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.

Other Formats

View All TNF-α Reagents Request Custom Conjugation
Description Clone Applications
Brilliant Violet 785™ anti-mouse TNF-α MP6-XT22 ICFC
APC/Cyanine7 anti-mouse TNF-α MP6-XT22 ICFC
PE/Dazzle™ 594 anti-mouse TNF-α MP6-XT22 ICFC
Brilliant Violet 711™ anti-mouse TNF-α MP6-XT22 ICFC
Brilliant Violet 750™ anti-mouse TNF-α MP6-XT22 ICFC
GoInVivo™ Purified anti-mouse TNF-α MP6-XT22 ELISA,ICFC,CyTOF®,ICC,IHC-F,WB,Neut
APC anti-mouse TNF-α MP6-XT22 ICFC
FITC anti-mouse TNF-α MP6-XT22 ICFC
PE anti-mouse TNF-α MP6-XT22 ICFC
Purified anti-mouse TNF-α MP6-XT22 ELISA,CyTOF®,ICC,ICFC,IHC-F,WB
Biotin anti-mouse TNF-α MP6-XT22 ELISA Detection,ELISPOT Detection,ICFC
Alexa Fluor® 488 anti-mouse TNF-α MP6-XT22 ICFC
Alexa Fluor® 647 anti-mouse TNF-α MP6-XT22 ICFC
Pacific Blue™ anti-mouse TNF-α MP6-XT22 ICFC
PerCP/Cyanine5.5 anti-mouse TNF-α MP6-XT22 ICFC
PE/Cyanine7 anti-mouse TNF-α MP6-XT22 ICFC
Brilliant Violet 421™ anti-mouse TNF-α MP6-XT22 ICFC
Ultra-LEAF™ Purified anti-mouse TNF-α MP6-XT22 ELISA,CyTOF®,ICC,ICFC,IHC-F,WB,Neut
Brilliant Violet 605™ anti-mouse TNF-α MP6-XT22 ICFC
Brilliant Violet 650™ anti-mouse TNF-α MP6-XT22 ICFC
Alexa Fluor® 700 anti-mouse TNF-α MP6-XT22 ICFC
Purified anti-mouse TNF-α (Maxpar® Ready) MP6-XT22 ELISA,CyTOF®
Brilliant Violet 510™ anti-mouse TNF-α MP6-XT22 ICFC
Spark NIR™ 685 anti-mouse TNF-α MP6-XT22 ICFC
TotalSeq™-C1529 anti-mouse TNF-α Antibody MP6-XT22 ICPG
TotalSeq™-B1529 anti-mouse TNF-α Antibody MP6-XT22 ICPG
Go To Top Version: 2    Revision Date: 10/14/2013

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account